Asymmetric dimethylarginine predicts survival in the elderly

Age

Volumn 35, Issue 6, 2013, Pages 2465-2475

  Pizzarelli, Francesco ^a   Maas, Renke ^b   Dattolo, Pietro ^a   Tripepi, Giovanni ^c   Michelassi, Stefano ^a   D'Arrigo, Graziella ^c   Mieth, Maren ^b   Bandinelli, Stefania ^a   Ferrucci, Luigi ^d   Zoccali, Carmine ^c  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^d National Institute on Agin   (United States)

Author keywords

ADMA; Cardiovascular risk factor; Elderly; Population study; Survival

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGININE; N(G),N(G) DIMETHYLARGININE;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HYPERTENSION; ITALY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; N(G),N(G) DIMETHYLARGININE BLOOD LEVEL; POPULATION RESEARCH; PREDICTION; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHROMATOGRAPHY, LIQUID; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84890038945     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/s11357-013-9523-1     Document Type: Article

References (32)

1. Achan V, BroadheadM,Malaki M, Whitler J, Leiper J, MacAllister R, Vallance P (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23:1455-1459
2. Ardigo D, Stuehlinger M, Franzini L, Valtuena S, Piatti PM, Pachinger O, Reaven GM, Zavaroni I (2007) ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 37:263-269
3. Bode-Boger SM, Scalera F, Martens-Lobenhoffer J (2005) Asymmetric dimethylarginine (ADMA) accelerates cell senescence. Vasc Med 10(Suppl 1):S65-S71
4. Boger RH (2004) Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 134:2842S-2847S
5. Boger RH, Bode-Boger SM, Szuba A et al (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842-1847
6. Boger RH, Maas R, Schulze F, Schwedhelm E (2009a) Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 60:481-487
7. Boger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS (2009b) Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119:1592-1600
8. Brenner T, Fleming TH, Rosenhagen C, Krauser U, Mieth M, Bruckner T, Martin E, Nawroth PP, Weigand MA, Bierhaus A, Hofer S (2012) L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure. Mediat Inflamm. doi:10.1155/2012/210454, article ID 210454
9. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL (2007) Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282:879-887
10. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, Gussekloo J (2009) Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338:a3083
11. Ferrucci L, Bandinelli S, Benvenuti E, Di Iorio A, Macchi C, Harris TB, Guralnik JM (2000) Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 48:1618-1625
12. Gerhard M, Roddy MA, Creager SJ, Creager MA (1996) Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 27:849-853
13. Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, Humphrey LL (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 151:496-507
14. Juonala M, Viikari JS, Alfthan G, Marniemi J, Kähönen M, Taittonen L, Laitinen T, Raitakari OT (2007) Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 116:1367-1373
15. Kannel WB (2002) Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol 11:101-107
16. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Filser D (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109:172-177
17. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A,Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM (2006) ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37:2024-2029
18. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, März W (2007) Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 53:273-283
19. Moncada S, Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012
20. Mukamal KJ, Kronmal RA, Tracy RP, Cushman M, Siscovick DS (2004) Traditional and novel risk factors in older adults: cardiovascular risk assessment late in life. Am J Geriatr Cardiol 13:69-80
21. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C (2005) Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46:518-523
22. Perticone F, Maio R, Perticone M, Miceli S, Sciacqua A, Tassone EJ, Shehaj E, Tripepi G, Sesti G (2010) Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 142:236-241
23. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16:2449-2455
24. Scalera F, Martens-Lobenhoffer J, Tager M, Bukowska A, Lendeckel U, Bode-Boger SM (2006) Effect of L-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial cell aging. Biochem Biophys Res Commun 345:1075-1082
25. Scalera F, Closs EI, Flick E, Martens-Lobenhoffer J, Boissel JP, Lendeckel U, Heimburg A, Bode-Böger SM (2009) Paradoxical effect of L-arginine: acceleration of endothelial cell senescence. Biochem Biophys Res Commun 386:650-655
26. Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse longterm outcome of coronary heart disease. Circulation 101:1899-1906
27. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E,Boger RH (2005) Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 35:622-626
28. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U,Boger RH (2007) High-throughput liquid chromatographictandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Anal Technol Biomed Life Sci 851:211-219
29. Tripepi G, Jager KJ, Dekker FW, Zoccali C (2008) Testing for causality and prognosis: etiological and prognostic models. Kidney Int 74:1512-1515
30. Tsikas D, Boger RH, Sandmann J, Bode-Boger SM, Frölich JC (2000) Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 478:1-3
31. Zoccali C (2006) Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 24:611-619
32. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117